Abstract
Background: Patients with moderate-to-severe atopic dermatitis (AD) experience skin lesions and intense itch that substantially affect quality of life. Patients have choices among systemic AD treatments that offer varied benefit–risk profiles. Objective: Measure patients’ willingness to trade off the risks and benefits of systemic treatments among individuals with a physician-confirmed diagnosis of moderate-to-severe AD. Methods: Patients participated in a discrete choice experiment online survey with a series of choices between hypothetical AD treatments defined by six attributes reflecting benefits and risks of treatments (itch reduction, time until noticeable itch reduction, chance of clear or almost clear skin, risk of serious infection, risk of developing acne, and need for prescription topical steroids). Data were analyzed with a random parameters logit model to quantify preferences and the relative importance of attributes for treatment alternatives. Results: Respondents (n = 200) placed the highest relative importance on itch reduction, speed of itch reduction, and skin clearance, and were generally willing to accept clinically relevant levels of risk of serious infection and acne in exchange for treatment benefits. Conclusions: Patients with moderate-to-severe AD were willing to trade clinically relevant treatment risks for greater or more rapid itch reduction and skin clearance offered by systemic therapies.
| Original language | English (US) |
|---|---|
| Article number | 2222201 |
| Journal | Journal of Dermatological Treatment |
| Volume | 34 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2023 |
Funding
Dr. Kwatra is an advisory board member/consultant for AbbVie, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals. He has served as an investigator for Galderma, Pfizer, and Sanofi. Dr. Lio has received research grants/funding from AbbVie, AOBiome, the National Eczema Association, and Regeneron/Sanofi Genzyme. He participates in speaker’s bureaus for Eli Lilly, Galderma, Incyte, L’Oreal, LEO Pharma, Pfizer, and Regeneron/Sanofi Genzyme. He reports payments for serving as a consultant or participating on advisory boards for AbbVie, Almirall, Amyris, AOBiome, Arbonne, Aslan, Bodewell, Bristol Myers Squibb, Burt’s Bees, Concerto Biosciences (stock options), Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, Kiniksa, LEO Pharma, L’Oreal, Menlo Therapeutics, Merck, Micreos (stock options), My-Or Diagnostics, Pierre-Fabre, Pfizer, Realm Therapeutics, Regeneron/Sanofi Genzyme, Sibel Health, Theraplex, UCB, Unilever, and Verrica. In addition, Dr. Lio has a patent pending for a Theraplex product and receives royalty payments for the patent. He is also a board member and scientific advisory committee member of the National Eczema Association. Dr. Weidinger is a speaker, advisory board member, and/or investigator for AbbVie, Almirall, Eli Lilly, Galderma, Kymab, LEO Pharma, Pfizer, Regeneron, and Sanofi. He has received research grants from La Roche Posay, LEO Pharma, Pfizer, and Sanofi Germany. Drs. Calimlim, Ladizinski, and Vigna are full-time employees of AbbVie Inc. and may own AbbVie stock and/or stock options. Dr. Botha is a former employee of RTI Health Solutions, which received funding from AbbVie Inc. to conduct the study. He was an employee of RTI Health Solutions at the time the study was conducted. Dr. Mansfield is a current employee of RTI Health Solutions, which received funding from AbbVie Inc. to conduct the study.
Keywords
- Atopic dermatitis
- conditional relative importance
- discrete choice experiment
- patient preference
ASJC Scopus subject areas
- Dermatology